Chinese Journal of Oncology 2004;26(12):739-741

Clinical trial on ibandronate in patients with tumor-associated hypercalcemia.

Tao WANG 1 ; San-tai SONG ; Ze-fei JIANG ; Shou-geng BIAN ; Ya-jie WANG ; Li-qing LI ; Jun ZHU

Affiliations

+expand

Country

China

Language

Chinese

MeSH

Abstract

OBJECTIVEIbandronate, a third generation bisphosphonate, inhibits bone resorption in human and animal studies. This study is to evaluate the efficacy and safety of ibandronate as a single agent in patients with tumor-associated hypercalcemia.

METHODSAn open, multicenter, non-controlled clinical trial was conducted in 22 patients. The patients received 2 mg ibandronate intravenously if the corrected calcium was less than 3.0 mmol/L but more than 2.7 mmol/L; they received 4 mg ibandronate iv if corrected calcium was more than 3.0 mmol/L.

RESULTSThere was 100% efficacy in these two dose groups but the calcium correcting effect was more pronounced in the 4-mg dose group than the 2-mg dose group. The most common adverse reactions were fever and skin itching with an incidence of 4.5%.

CONCLUSIONIbandronate is active in patients with tumor-associated hypercalcemia and the adverse effects are well tolerated.